About KIDS
Home Overview About KIDS
Legal Basis
Legal basis
Article 68-3 of 「Pharmaceutical Affairs Act」
Establishment on
06 Jan 2012 (Designated as public institution: 31 Jan 2013)
Main business
- To investigate ADR causality, such as medication accidents
- To collectㆍanalyzeㆍassessㆍmanage and provide drug safety information
- To engage in investigationㆍresearch and training: promotion for development/use of drug safety information
- Investigation of adverse drug effects and calculation, imposition, collection, and management of charges
- To collectㆍmanageㆍinvestigateㆍuse and provide the reported information in connection with the handlingㆍmanagement of narcotics
- To engage in researchㆍtraining and promotion regarding the standardization of narcotics information
- Long-term follow-up investigation of advanced Biological Products and comprehensive information and technology support
Mission and Vision
Organization Chart
- President
- Office of Audit
-
-
- Department of Strategic Management
- Office of Strategic Planning
- Office of Management Support
- Office of Informatization
- Task Force of Integrated Pharmaceutical Information System
-
- DDepartment of Drug Safety Information
- Office of Drug Safety Information
- Office of Pharmacoepidemiology and Big Data Analytics
- Office of Drug Utilization Review
- Task Force of Education and Research
-
- Department of ADR Relief
- Office of ADR Relief Investigation
- Office of ADR Relief Administration
-
- Department of Narcotics Information Management
- Office of Narcotics Information Management
- Office of Narcotics System Development
- Office of Narcotics Reporting Assistance
- Task Force of Narcotics Information Analytics
-
History
- 2022
- 00.00Accomplished excellent grade in management performance evaluation by Ministry of Food and Drug Safety
- 2021
- 00.004th President Jeong Wyan Oh inauguration
- 00.00Accomplished excellent grade in management performance evaluation by
Minitry of Food and Drug Safety 2022
- 2020
- 09.23Designated as the Regulatory Science Center for Advanced Therapy Medicinal Products
- 07.09Excellence Award from the Ministry of Food and Drug Safety’s Business Performance
- 03.16Excellence Award from the Ministry of Food and Drug Safety’s Corruption Prevention Policy
- 2019
- 12.06Operation of the “Integrated Pharmaceutical Information System”
- 11.11Excellence Award from the Ministry of Food and Drug Safety’s
Innovative Public Institution Competition
- 2018
- 12.032018 Safety Culture Excellence Award (citation from the Minister of the Interior and Safety)
- 07.253rd President Soon Young Han inauguration
- 05.25WHO United Arab Amirates(UAE) Health Foundation Prize
- 05.18Implementation of Reporting on Narcotics Handing System
- 2017
- 08.18Endorsement as formal APEC PV Center of Excellence(CoE)
- 04.145th anniversary ceremony and symposium
- 2016
- 09.06Operation of APEC PV Center of Excellence(CoE) Pilot Program
- 2015
- 07.20Designated as a Center for Narcotics Information Management
- 02.132nd President Bon Ki Koo inauguration
- 2014
- 12.19Korea ADR Relief program was launched
- 10.10Designated as a PV training center
- 08.20Collection of foreign adverse event reports
- 2013
- 04.171st anniversary symposium
- 01.31Designated as public institution
- 2012
- 11.01ADR call center established
- 10.01Establishment of KAERS to receive adverse event reports and collection of local ADR cases
- 04.17Opening ceremony and symposium
- 02.061st President Byung Joo Park inauguration
- 01.06Establishment of Korea Institute of Drug Safety and Risk Management
Location
Korea Institute of Drug Safety and Risk Management Address :
4-6th Fl., 30, Burim-ro 169beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, Republic of Korea (For more information, visit www.drugsafe.or.kr)